Treatment of patients with stages I and II nonmediastinal Hodgkin's disease

Journal Article · Wed Dec 01 04:00:00 EST 1982 · Cancer (Philadelphia); (United States)

DOI:https://doi.org/10.1002/1097-0142(19821201)50:11<2307::AID-CNCR2820501115>3.0.CO;2-Z· OSTI ID:6516167

Hagemeister, F B; Fuller, L M; Sullivan, J; Johnston, D; North, L; Butler, J J; Velasquez, W S; Shullenberger, C C

In this study, 95 patients with laparotomy-staged I and II nonmediastinal Hodgkin's disease were treated with involved fields (41 patients), mantle (17), extended fields (26), or involved fields followed by 6 cycles of chemotherapy (11). Eighty-five patients had upper torso presentations. Seventy had Stage I disease and 25 had stage II. Pathologic findings were nodular sclerosing, 33; mixed cellularity, 41; lymphocyte predominance, 20; and unclassified, one. Five-year overall survivals were excellent regardless of stage, pathologic findings, or treatment: 98% for involved fields or mantle, and 100% for both extended fields and involved fields followed by 6 cycles of chemotherapy. Corresponding disease-free survivals were 77%, 82%, and 86%, respectively. For patients with upper torso presentations, disease-free figures for the mantle (94%) were better than those for involved fields alone (67%). In addition, regression analysis proved involved fields to be a prognostic factor for a lower disease-free survival. No difference between extended fields or mantle radiotherapy could be detected using this model. Relapses usually occurred in nonirradiated upper torso sites. Only three of the 36 patients treated with involved fields and one of 21 treated with extended fields relapsed in the abdomen alone. Most patients in relapse were salvaged. Rescue treatment was most often radiotherapy and adjuvant combination chemotherapy. Based on this study, the use of mantle radiotherapy is recommended in treating laparotomy-staged I and II patients with nonmediastinal presentations, and the use of extended fields or adjuvant chemotherapy as primary prevention is not recommended. (JMT)

• Research Organization: The Univ. of Texas System Cancer Center, Houston
• OSTI ID: 6516167
• Journal Information: Cancer (Philadelphia); (United States), Journal Name: Cancer (Philadelphia); (United States) Vol. 50:11; ISSN CANCA
• Country of Publication: United States
• Language: English

Related Subjects

550603* -- Medicine-- External Radiation in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
CHEMOTHERAPY
COMPARATIVE EVALUATIONS
DISEASES
FRACTIONATED IRRADIATION
HODGKINS DISEASE
IRRADIATION
LYMPH NODES
LYMPHATIC SYSTEM
LYMPHOMAS
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
PATIENTS
RADIOLOGY
RADIOTHERAPY
SURVIVAL TIME
THERAPY